Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
Journal of Cancer Research and Clinical Oncology
Published in: Journal of Cancer Research and Clinical Oncology 2/2003

01-02-2003 | Original Paper

Changes in matrix metalloproteinases and their endogenous inhibitors during tumor progression in the uterine cervix

Authors: S. Asha Nair, D. Karunagaran, M. B. Nair, P. R. Sudhakaran

Published in: Journal of Cancer Research and Clinical Oncology | Issue 2/2003

Login to get access

Abstract

Purpose

To study the role of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in cervical tumorigenesis, we analyzed 70 cervical tissue specimens that included 15 low-grade squamous intraepithelial lesions (SILs), 20 high-grade SILs, 25 squamous cell carcinomas (SCCs) and 10 specimens of normal cervical tissue.

Methods

The gelatinolytic activity of MMP-9 and MMP-2 was determined by zymographic analysis. The expression of MMP-9 and MMP-2 and TIMP-1 and TIMP-2 was determined by immunohistochemistry.

Results

All the samples had 72/66 kDa gelatinase activity; 92 kDa gelatinase activity was detected only in high-grade SILs and SCCs. Immunohistochemical analysis showed weak positivity for MMP-2 in normal cervical epithelium and low-grade SILs. However, high-grade SILs and SCCs showed intense cellular and stromal reactivity for MMP-2 and MMP-9. For TIMP-1 and TIMP-2, normal cervical epithelium and low-grade SILs showed intense immunostaining, >50% of high-grade SILs showed positivity, and 95% of SCCs showed intense stromal and cellular reactivity.

Conclusions

Increase in the relative activity of these gelatinases and enhanced immunostaining for MMPs and TIMPs with tumor progression suggest that they may play a crucial role in cervical cancer progression. A significant association between stage of the lesion and expression of MMPs and TIMPs (P<0.01) was found. Immunohistochemical studies indicate that these MMPs may be of basal cell origin in cervical tissue, although the mechanism of their upregulation is not clearly understood.
Literature
Afzal S, Lalani EN, Foulkes WD, Boyce B, Tickle S, Cardillo MR, Baker T, Pignatelli M, Stamp GWH (1996) Matrix metalloproteinase-2 expression and synthetic matrix metalloproteinase-2 inhibitor binding in ovarian carcinomas and tumor cell lines. Lab Invest 74:406–421PubMed
Ambili M, Sudhakaran PR (1999) Modulation of neutral matrix metalloproteinases of involuting rat mammary gland by different cations and glycosaminoglycans. J Cell Biochem 73:218–226
Arenas F, Villa S, Solarza G, Raminez JL, de la Garza L (1995) Correlation between response to therapy and levels of metalloproteinases (MMPs) secreted in vitro in carcinoma of the cervix (CaCx). Proc Am Assoc Cancer Res 14:A817
Basbaum CB, Werb Z (1996) Focalized proteolysis spatial and temporal regulation of extracellular matrix at cell surface. Curr Opin Cell Biol 8:731–738CrossRefPubMed
Birkedal-Hansen H (1995) Proteolytic remodeling of extracellular matrix. Curr Opin Cell Biol 7:728–735
Brummer O, Bohmer G, Hollwitz B, Flemming P, Petry KU, Kuhnle H (2002) MMP-1 and MMP-2 in the cervix uteri in different steps of malignant transformation—an immunohistochemical study. Gynecol Oncol 84:222–227CrossRefPubMed
Campo E, Tavassoli FA, Charonis AS, Stetler-Stevenson WG, Liotta LA, Merino MJ (1992) Evaluation of basement membrane components and 72-kDa type IV collagenase in serous tumors of the ovary. Am J Pathol 6:500–507
Crawford HC, Matrisian LM (1995) Tumor and stromal expression of matrix metalloproteinases and their role in tumor progression. Invasion Metastasis 14:234–245
Davidson B, Goldberg I, Kopolovic J, Lerner Geva L, Gotlieb WH, Weis B, Ben-Baruch G, Reich R (1999a) Expression of metalloproteinase-9 in squamous cell carcinoma of the uterine cervix—clinicopathologic study using immunohistochemistry and mRNA in situ hybridization. Gynecol Oncol 72:380–386CrossRefPubMed
Davidson B, Goldberg I, Kopolovic J, Lerner Geva L, Gotlieb WH, Weis B, Ben-Baruch G, Reich R (1999b) MMP-2 and TIMP-2 expression correlates with poor prognosis in cervical carcinomas—a clinicopathologic study using immunohistochemistry and mRNA in situ hybridization. Gynecol Oncol 73:372–382PubMed
De Clerck YA, Perez N, Shimada H, Boone TC, Langley KE, Taylor SM (1992) Inhibition of invasion and metastasis in cell transfected with an inhibitor of metalloproteinases. Cancer Res 52:701–708PubMed
De Clerck YA, Shimada H, Taylor SM, Langley KE (1994) Matrix metalloproteinases and their inhibitors in tumor progression. Ann N Y Acad Sci 732:222–232PubMed
De'Errico A, Garbisa S, Liotta LA, Castronovo V, Stetler-Stevenson WG, Griogioni WG (1991) Augmentation of type-IV collagenase, laminin receptor, and Ki 67 proliferation antigen associated with human colon, gastric and breast carcinoma progression. Mod Pathol 4:239–246PubMed
Denhardt DT, Feng B, Edwards DR, Cocuzzi ET, Malyankar UM (1993) Tissue inhibitor of metalloproteinases (TIMP, akaEPA): structure, control of expression and biological function. Pharmacol Ther 59:329–341PubMed
Gilles C, Polette M, Pielta J, Manaut C, Thompson EW, Birembaut P, Foidart JM (1996) High level of MT-MMP expression is associated with invasiveness of cervical cancer cells. Int J Cancer 65:209–213CrossRefPubMed
Greene L, Wang M, Xiao G, Liu YE, Shi YE (1996) Loss of expression of TIMP-4 a novel human tissue inhibitor of metalloproteinase in human breast cancer progression. Proc Am Assoc Cancer Res 37:91
Hoyhtya M, Fridman R, Komarck D, Porter-Jordan K, Stetler Stevenson WJ, Liotta LA, Liang CM (1994) Immunohistochemical localization of matrix metalloproteinase 2 and its specific inhibitor TIMP-2 in neoplastic tissue with monoclonal antibodies. Int J Cancer 56:500–505PubMed
Iwasaki M, Nishikawa A, Fujimoto T, Akutgawa N, Manase K, Endo T, Yoshida K, Maekawa R, Yoshioka T, Kudo R (2002) Anti-invasive effect of MMI-166, a new selective matrix metalloproteinase inhibitor, in cervical carcinoma cell lines. Gynecol Oncol 85:103–107CrossRefPubMed
Iwata H, Iwase H, Koboyashi S (1995) Invasion and metastasis of breast cancer matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPS). Biotherapy 9/11:1359–1366
Kato Y, Yamashita T, Ishikawa M (2002) Relationship between expression of matrix metalloproteinase-9 and invasion ability of cervical cancer cells. Oncol Rep 9:565–569PubMed
Kusukawa J, Sasaguri Y, Shima I, Kameyama T, Morimatsu M (1993) Expression of matrix metalloproteinase 2 related to lymph node metastasis of oral squamous cell carcinoma: a clinicopathologic study. Am J Clin Pathol 99:18–23PubMed
Levy A, Cioce V, Sobel ME, Garbisa S, Griogioni WF, Liotta LA (1991) Increased expression of the 72 kDa type IV collagenase in human colonic adenocarcinoma. Cancer Res 51:439–444
Monteagudo C, Merino MJ, SanJuan J, Liotta LA, Stetler Stevenson WJ (1990) Immunohistochemical distribution of type IV collagenase in normal, benign and malignant breast tissue. Am J Pathol 136:585–592PubMed
Moser PL, Kieback DG, Hefler L, Tempfer C, Neunteufel W, Gitsch G (1999) Immunohistochemical detection of matrix metalloproteinases (MMP) 1 and 2, and tissue inhibitor of metalloproteinase 2 (TIMP 2) in stage 1B cervical cancer. Anticancer Res 19:4391–4393PubMed
Nair AS, Nair MB, Jayaprakash PG, Rajalekshmi TN, Nair MK, Pillai MR (1997) The basement membrane and tumor progression in the uterine cervix. Gen Diag Pathol 142:297–303
Nair AS, Nair MB, Jayaprakash PG, Rajalekshmy TN, Nair MK, Pillai MR (1998) ras and c-myc oncoproteins during tumor progression in the uterine cervix. Tumori 84:583–588PubMed
Naylor MS, Stamp GWH, Davies B, Balkwill FR (1994) Expression and activity of MMPs and their regulators in ovarian cancer. Int J Cancer 58:50–56PubMed
Poulsom R, Pignatelli M, Stetler-Stevenson WG, Liotta LA, Wright PA, Jeffrey RE, Longcroft J, Roger L, Stamp GWH (1992) Stromal expression of 72kda type IV collagenase (MMP-2) and TIMP-2 mRNAs in colorectal neoplasia. Am J Pathol 141:389–396PubMed
Pyke C, Ralfkiaer E, Tryggvason K, Dano K (1993) Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer. Am J Pathol 142:359–365PubMed
Takemura M, Azuma C, Kimura T, Kanai T, Saji F, Tanizawa O (1994) Type-IV collagenase and tissue inhibitor of metalloproteinase in ovarian cancer tissues. Int J Gynecol Obstet 46:303–309
Talvensaari-Mattila A, Apaja-Sarkkinen M, Hoyhtya M, Westerlund A, Puistola U, Turpeenniemi-Hujanen T (1999) Matrix metalloproteinase 2 immunoreactive protein appears early in cervical epithelial differentiation. Gynecol Oncol 72:306–311CrossRefPubMed
Tamakoshi K, Kikawa F, Nawa A, Ishikawa H, Mizuno K, Tamakoshi A, Yamagata S, Suganuma N, Tomoda Y (1995) Characterization of extracellular matrix-degrading proteinase and its inhibitors in gynecological cancer tissue with clinically different metastatic form. Cancer 76:2561–2571
Thomas GT, Lewis MP, Speight PM (1999) Matrix metalloproteinases and oral cancer. Oral Oncol 35:227–233CrossRefPubMed
Toki N, Kaku T, Tsukamoto N, Marsumura M, Saito T, Kamura T, Matsuyama T, Nakano H (1990) Distribution of basement membrane antigens in the uterine cervical adenocarcinomas: an immunohistochemical study. Gynecol Oncol 38:17–21PubMed
Tsuboi R, Yamaguchi T, Nakao H, Ogawa H, Ishihara K (1988) Comparison of proteinase activities in squamous cell carcinoma, basal cell epithelium, and seborrheic keratosis. J Invest Dermatol 90:869–872PubMed
Visscher DW, Hoyhtya M, Ottosen SK, Liang CM, Sarkar FH, Crissman JD, Fridman R (1994) Enhanced expression of tissue inhibitor of metalloproteinase-2 (TIMP-2) in the stroma of breast carcinomas correlates with tumor recurrence. Int J Cancer 59:339–344PubMed
Werb Z (1997) ECM and cell surface proteolysis regulating cellular ecology. Cell 91:439–442PubMed
Metadata
Title
Changes in matrix metalloproteinases and their endogenous inhibitors during tumor progression in the uterine cervix
Authors
S. Asha Nair
D. Karunagaran
M. B. Nair
P. R. Sudhakaran
Publication date
01-02-2003
Publisher
Springer-Verlag
Published in
Journal of Cancer Research and Clinical Oncology / Issue 2/2003
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-002-0411-9

Other articles of this Issue 2/2003

Journal of Cancer Research and Clinical Oncology 2/2003 Go to the issue

Original Paper

Pretreatment clinical prognostic factors in patients with stage IV non-small cell lung cancer (NSCLC) treated with chemotherapy

Original Paper

Loss of FHIT protein expression correlates with disease progression and poor differentiation in gastric cancer

Original Paper

Cytogenetics and cytology of retinoblastomas

Original Paper

Increased susceptibility to the tobacco carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in transgenic mice overexpressing c-myc and epidermal growth factor in alveolar type II cells

Original Paper

Cloning and functional characterization of GMPR2, a novel human guanosine monophosphate reductase, which promotes the monocytic differentiation of HL-60 leukemia cells

Original Paper

The alteration of PTEN tumor suppressor expression and its association with the histopathological features of human primary hepatocellular carcinoma

ACC 2024 Congress Coverage

Cardiology Video

Highlights from the ACC 2024 Congress

Watch now

Watch official videos from the ACC congress summarizing key highlights from the last year in heart failure, cardiomyopathies, valvular disease, pulmonary vascular disease, and pediatric cardiology.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits